Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13206629 | 1.00 | EGFR (0.38) | EGFRKDM4ECISD1SLC16A3ALDH1A1 | |
| SCHEMBL30682963 | 1.00 | EGFR (0.38) | EGFRKDM4ECISD1SLC16A3ALDH1A1 | |
| SCHEMBL30682965 | 1.00 | EGFR (0.38) | EGFRKDM4ECISD1SLC16A3ALDH1A1 | |
| SCHEMBL18959027 | 0.81 | MEN1 (0.34) | EGFRALDH1A1KMT2A | |
| SCHEMBL15710434 | 0.79 | EGFR (0.45) | EGFRKDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL19421178 | 0.79 | MEN1 (0.49) | EGFRALDH1A1KMT2A | |
| SCHEMBL13857847 | 0.79 | MEN1 (0.33) | EGFRALDH1A1KMT2A | |
| SCHEMBL13857846 | 0.79 | MEN1 (0.33) | EGFRALDH1A1KMT2A | |
| SCHEMBL15710430 | 0.79 | EGFR (0.45) | EGFRKDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL32684869 | 0.77 | KDM4E (0.33) | EGFRKDM4ECISD1SLC16A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9752049-B2 | Optically transparent, superhydrophobic, biocompatible thin film coatings and methods for producing same | UT-BATTELLE, LLC (US) | 2017-09-05 | — | — | US | claimed |
| US-20150232690-A1 | OPTICALLY TRANSPARENT, SUPERHYDROPHOBIC, BIOCOMPATIBLE THIN FILM COATINGS AND METHODS FOR PRODUCING SAME | UT-BATTELLE, LLC (US) | 2015-08-20 | — | — | US | claimed |
| EP-1100380-B1 | BIOABSORBABLE BLENDS AND SURGICAL ARTICLES THEREFROM | TYCO HEALTHCARE (US) | 2011-11-02 | — | — | EP | claimed |
| EP-1455738-B1 | USE OF ELECTROPHILIC MONOMERS FOR HAIR TREATMENT | OREAL (FR) | 2010-07-28 | — | — | EP | claimed |
| EP-1360257-B1 | CYANOACRYLATE COMPOSITIONS CURABLE TO FLEXIBLE POLYMERIC MATERIALS | LOCTITE R & D LTD (IE) | 2007-07-25 | — | — | EP | claimed |
| US-6977278-B1 | Cyanoacrylate compositions curable to flexible polymeric materials | LOCTITE (R&D) LTD. (IE) | 2005-12-20 | — | — | US | claimed |
| WO-2004024467-A2 | SURFACE-MOUNTING SYSTEM | LOCTITE (R & D) LIMITED (IE) | 2004-03-25 | — | — | WO | claimed |
| EP-1360257-A1 | CYANOACRYLATE COMPOSITIONS CURABLE TO FLEXIBLE POLYMERIC MATERIALS | Loctite (R & D) Limited (IE) | 2003-11-12 | — | — | EP | claimed |
| WO-2002053666-A1 | CYANOACRYLATE COMPOSITIONS CURABLE TO FLEXIBLE POLYMERIC MATERIALS | LOCTITE (R & D) LIMITED (IE) | 2002-07-11 | — | — | WO | claimed |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2026-01-22 | — | — | US | disclosed |
| EP-3181567-B9 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2007054113-A1 | ADHESIVES, SEALANTS AND COATINGS CONTAINING GLASS PARTICLES AS A FILLER | HENKEL AG & CO. KGAA (DE) | 2007-05-18 | — | — | WO | disclosed |
| US-6977278-B1 | Cyanoacrylate compositions curable to flexible polymeric materials | LOCTITE (R&D) LTD. (IE) | 2005-12-20 | — | — | US | disclosed |
| WO-2004024467-A2 | SURFACE-MOUNTING SYSTEM | LOCTITE (R & D) LIMITED (IE) | 2004-03-25 | — | — | WO | disclosed |
| EP-1360257-A1 | CYANOACRYLATE COMPOSITIONS CURABLE TO FLEXIBLE POLYMERIC MATERIALS | Loctite (R & D) Limited (IE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002053666-A1 | CYANOACRYLATE COMPOSITIONS CURABLE TO FLEXIBLE POLYMERIC MATERIALS | LOCTITE (R & D) LIMITED (IE) | 2002-07-11 | — | — | WO | disclosed |
| WO-1999023150-A1 | CYANOACRYLATE POLYMER COMPOSITIONS COMPRISING AN ANTIMICROBIAL AGENT | MEDLOGIC GLOBAL CORPORATION (US) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | BTK, TEC, SYK | EGFR 637/4885KDM4E 287/4885CISD1 2096/4885 |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | EGFR 633/4885KDM4E 3785/4885CISD1 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.